Hbot denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hbot are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Hyperbaric Oxygen Therapy for Quantity-Limit Reasons

UHC applies quantity limits to HBOT — typically a cap on the number of sessions authorized per course of treatment or per calendar year. A quantity-limit denial means the claim exceeds the number of sessions UHC's policy permits without additional clinical justification. These limits are not absolute; UHC's own policy generally allows for extensions when the patient has shown measurable clinical response but has not yet reached treatment goals. Denials occur when the extension request is missing or inadequately supported.

## Why This Denial Is Appealable

Quantity-limit denials are appealed on the grounds that continued treatment is medically necessary for this specific patient — that the condition has not resolved, that measurable progress is ongoing, and that stopping at the policy limit would result in a clinically significant setback. The key is objective documentation of incremental improvement. Under ACA §2719, you have internal appeal rights and IRO access. ERISA §503 applies to employer plans. The external-review window runs approximately four months from the denial; expedited review is available when stopping treatment poses urgent risk.

## The Appeal Process

1. Obtain the quantity-limit threshold from UHC's policy — not to rely on a number here, but to document exactly what the policy states so the appeal can show the patient meets the extension criteria. 2. File a Level 1 internal appeal focused on medical necessity for continued treatment, supported by progress documentation. 3. Request a peer-to-peer review between the treating clinician and UHC's medical director — this often resolves quantity-limit appeals faster than a written submission. 4. If denied internally, proceed to external review through UHC's IRO.

## Documentation to Gather

• Session-by-session progress notes: Objective wound measurements, photography (if used), transcutaneous oxygen readings, or other quantified markers showing the treatment trajectory.
• Clinical response documentation: Before-and-after comparisons demonstrating measurable improvement that supports continued treatment.
• Prognosis statement: Prescriber letter explaining what additional sessions are expected to achieve, with a defined endpoint and rationale grounded in the applicable professional-society guidelines.
• Consequence of stopping: Clinical assessment of what will happen if treatment is discontinued — wound regression, infection risk, amputation risk, etc. — stated in the prescriber's own words.
• UHC policy extension criteria: Copy the extension criteria from UHC's HBOT policy and document how the patient meets each one.

## Criteria-Mapping Structure

Pull the extension criteria from UHC's current HBOT medical policy. For each criterion:

| UHC Extension Criterion | Patient Evidence | |---|---| | [Copy criterion verbatim from policy] | [Specific note date, measured value, and clinician interpretation] |

Include a summary graph or table of wound measurements over the treatment course if available — visual evidence of a healing trajectory is often the most persuasive element in a quantity-limit appeal.